KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System

OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System

WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (“EOS”). This represents the company’s 80th system designed to treat musculoskeletal issues in children.

VerteGlide is a guided growth technology designed for children with Early Onset Scoliosis, a severe and sometimes life-threatening condition affecting kids under the age of 10, who often suffer from pulmonary and digestive dysfunction because of the deformity.   VerteGlide represents the second in a series of technologies OrthoPediatrics is developing to address the challenges of this special group of children suffering from debilitating and life-threatening consequences of Early Onset Scoliosis. With its unique design, the VerteGlide Spinal Growth Guidance System is designed to allow for deformity correction and minimize repeat surgeries needed until skeletal maturity.  With the recent FDA clearance of this device, the Company is preparing for a limited launch and expects to be doing initial surgeries with select children's centers during summer of this year.  

Dr. Richard McCarthy, a pediatric orthopedic spine surgeon in Louisville, Kentucky is a pioneer in the field of growth guidance in scoliosis surgery; he and Dr. Scott Luhmann of St. Louis have been instrumental in partnering with the Company on the design and development of the system. McCarthy shared that "VerteGlide marks a breakthrough in technology for children."

OrthoPediatrics Scoliosis division President, Greg Odle commented “We are excited to introduce another new product to treat children with EOS. The team has been working with key opinion leaders from the surgeon community to identify new technologies that will help this particularly vulnerable patient population. VerteGlide’s launch represents our commitment to treating the entire disease state of scoliosis.”

CEO, David Bailey echoed those comments, saying “I’m incredibly proud of the Engineering team and the work the business teams have done to bring this product to market. It feels like we are making meaningful progress in providing healthcare professionals innovative treatment options for the patients they serve.”

The VerteGlide Spinal Growth Guidance System is made possible with the Shilla™ technology licensed from Medtronic.

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit

Investor Contact

Philip Trip Taylor

Gilmartin Group



415-937-5406



EN
08/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results

OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results Increased Third Quarter 2025 Revenue 12% Year-over-year, and Increased Adjusted EBITDA by 56% year-over-year WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 and Recent Business Highlights       Helped over 37,000 children in the third quarter of 2025 and approximat...

 PRESS RELEASE

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating ...

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the FDA approval of its 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family. This represents the company’s 6th FDA approval in 2025. The 3P Small-Mini System is a versatile plate and s...

 PRESS RELEASE

OrthoPediatrics Corp. to Report Third Quarter Financial Results on Oct...

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025 WARSAW, Ind., Oct. 15, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2025 financial results on October 28, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, October 28, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference ...

 PRESS RELEASE

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue...

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook WARSAW, Ind., Oct. 09, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the third quarter ended September 30, 2025, and revised 2025 financial guidance. Preliminary Third Quarter 2025 Results...

 PRESS RELEASE

OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spin...

OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spinal Growth Guidance System WARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the first U.S. surgical procedures with the VerteGlide Spinal Growth Guidance System (“VerteGlide”), used to treat Early Onset Scoliosis (“EOS”). Dr. Richard McCarthy, a pediatric orthopedic spine surgeon in Louisville, Kentucky who, along with Dr. Kent Wa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch